Heim C, Münzer T, Listyo R
Institut für Anästhesiologie, Kantonsspital St. Gallen.
Anaesthesist. 1994 Aug;43(8):504-9. doi: 10.1007/s001010050085.
Ondansetron is more effective than a placebo in treating postoperative nausea and vomiting (PONV), but it has not been proved to be superior to established antiemetics for prophylaxis or therapy. We compared ondansetron vs droperidol for the treatment of PONV.
Our prospective, randomized double-blind study was performed between 15 October 1992 and July 1993; it included 271 gynaecological ASA I-III inpatients who had been operated on under general anaesthesia with intubation. Patients were excluded if: there was no informed consent; it was an ambulatory or emergency operation; the patient was pregnant or breast feeding; allergies were being treated with antihistamines; drug addiction was present or convulsions or Parkinson's disease; any pre- or intraoperative antiemetic medication had been administered. All patients wishing an antiemetic and/or suffering from at least one emetic episode during the first 24 h postoperatively received either 8 mg ondansetron or 1.25 mg droperidol from identical 4 ml ampoules intravenously. The verbal nausea score (1 = none, 2 = mild, 3 = moderate, 4 = severe) was recorded every 30 min for 4 h, then before and 2 h after each antiemetic dose. All emetic episodes and the interval between administration and effect were also noted. Patients were interviewed 36-48 h postoperatively on subjective effects, side-effects and individual acceptance. After oral premedication with diazepam, anaesthesia was induced with thiopental, in a few cases with etomidate or propofol. Relaxation was achieved with pancuronium or atracurium and, when indicated, with succinylcholine. Muscular relaxation was antagonized with neostigmine and glycopyrrolate. Gastric content was aspirated once after intubation. Anaesthesia was maintained with nitrous oxide/oxygen, enflurane, halothane or isoflurane and fentanyl up to 0.3 mg. Statistical evaluation was performed by the unpaired Student's t-test and the Mann-Whitney U test. Categoric variables were examined by the chi 2 test. Significance was defined as P < 0.05.
Of 271 patients, 100 (37%) experienced PONV. The groups were statistically comparable with respect to demographic data, type and duration of operation, emesis record, perioperative uterotonic medication. Twenty patients in the ondansetron group and 27 in the droperidol group received the first antiemetic within 2 h, the other patients up to 17 h after extubation. Nausea scores and emetic episodes were identical before antiemetic medication. The reduction of these parameters after medication was similar. Complete response over 6 h was 60% in the ondansetron and 68% in the droperidol group. In both groups the first medication failed in 4 cases during the initial 2 h. Twenty of the ondansetron and 16 of the droperidol patients needed a second dose; among these 2 and 4, respectively, a third ampoule. No rescue medication was necessary over 24 h and a mean of 1.4 ampoules was administered in both groups. Onset and quality of emetic action were identical in both groups. It was not possible to evaluate 25 interviews due to linguistic or amnestic problems. Multiple side-effects were noted frequently. Injection pain was reported significantly more often in the droperidol, pruritus in the ondansetron group. Ninety-three percent of the ondansetron and 85% of the droperidol patients opted for the same drug for future PONV treatment.
Ondansetron (8 mg) and droperidol (1.25 mg) proved to be equally effective when used as a postoperative antiemetic. Both drugs showed similar side-effects. Due to differences in methods it was difficult to compare our results to those obtained in other studies.
昂丹司琼在治疗术后恶心和呕吐(PONV)方面比安慰剂更有效,但尚未被证明在预防或治疗方面优于已有的止吐药。我们比较了昂丹司琼与氟哌利多治疗PONV的效果。
我们的前瞻性、随机双盲研究于1992年10月15日至1993年7月进行;纳入了271例ASA I-III级接受全身麻醉插管手术的妇科住院患者。若患者存在以下情况则被排除:未获得知情同意;为门诊或急诊手术;患者怀孕或正在哺乳;正在使用抗组胺药治疗过敏;存在药物成瘾或惊厥或帕金森病;术前或术中已使用任何止吐药物。所有希望使用止吐药和/或术后24小时内至少经历一次呕吐发作的患者,均从相同的4毫升安瓿中静脉注射8毫克昂丹司琼或1.25毫克氟哌利多。每30分钟记录一次言语恶心评分(1 = 无,2 = 轻度,3 = 中度,4 = 重度),共记录4小时,然后在每次止吐药给药前及给药后2小时记录。还记录了所有呕吐发作情况以及给药与起效之间的间隔时间。术后36 - 48小时对患者进行访谈,了解主观效果、副作用和个人接受程度。口服地西泮进行术前用药后,用硫喷妥钠诱导麻醉,少数情况下用依托咪酯或丙泊酚。用潘库溴铵或阿曲库铵实现肌肉松弛,必要时加用琥珀胆碱。用新斯的明和格隆溴铵拮抗肌肉松弛作用。插管后抽吸一次胃内容物。用氧化亚氮/氧气、恩氟烷、氟烷或异氟烷和芬太尼维持麻醉,芬太尼用量可达0.3毫克。采用成组设计t检验和Mann-Whitney U检验进行统计学评估。分类变量采用卡方检验。显著性定义为P < 0.05。
271例患者中,100例(37%)发生PONV。两组在人口统计学数据、手术类型和持续时间、呕吐记录、围手术期宫缩剂用药方面具有统计学可比性。昂丹司琼组20例患者和氟哌利多组27例患者在2小时内接受了首次止吐药治疗,其他患者在拔管后17小时内接受治疗。止吐药用药前恶心评分和呕吐发作情况相同。用药后这些参数的降低情况相似。昂丹司琼组6小时完全缓解率为60%,氟哌利多组为68%。两组在最初2小时内均有4例首次用药无效。昂丹司琼组20例患者和氟哌利多组16例患者需要第二剂药物;其中分别有2例和4例需要第三支安瓿。24小时内无需抢救药物,两组平均给药量均为1.4支安瓿。两组呕吐起效时间和效果相同。由于语言或记忆问题,25份访谈无法进行评估。经常观察到多种副作用。氟哌利多组注射疼痛报告显著更多,昂丹司琼组瘙痒报告更多。93%的昂丹司琼患者和85%的氟哌利多患者选择相同药物用于未来PONV治疗。
昂丹司琼(8毫克)和氟哌利多(1.25毫克)作为术后止吐药效果相当。两种药物副作用相似。由于方法不同,难以将我们的结果与其他研究结果进行比较。